US20150374998A1 - Approval per use implanted neurostimulator - Google Patents
Approval per use implanted neurostimulator Download PDFInfo
- Publication number
- US20150374998A1 US20150374998A1 US14/849,351 US201514849351A US2015374998A1 US 20150374998 A1 US20150374998 A1 US 20150374998A1 US 201514849351 A US201514849351 A US 201514849351A US 2015374998 A1 US2015374998 A1 US 2015374998A1
- Authority
- US
- United States
- Prior art keywords
- patient
- therapy
- controller
- neurostimulator
- database
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37235—Aspects of the external programmer
- A61N1/37247—User interfaces, e.g. input or presentation means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36142—Control systems for improving safety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37235—Aspects of the external programmer
- A61N1/37241—Aspects of the external programmer providing test stimulations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37252—Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data
- A61N1/37282—Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data characterised by communication with experts in remote locations using a network
-
- G06F19/3406—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
- A61N1/36075—Headache or migraine
Definitions
- This invention is directed to an active implantable device that has features that facilitate the metered prescription of use over time, which is particularly relevant for devices that can dispense a large amount or otherwise unlimited amount of therapy without external intervention.
- the invention may be applied to a range of implantable medical devices including without limitation implantable drug pumps, functional electrical neurostimulators, such as spinal cord stimulators, stimulators for incontinence and deep brain stimulators. This disclosure will focus on an implantable neurostimulator used to treat headache.
- implantable medical devices that are loaded with or are otherwise able to administer or deliver a large or unlimited amount of therapy.
- an implanted drug pump could contain many years worth of drug, or an inductively powered, rechargeable, or primary cell implantable stimulator could deliver therapy in perpetuity as governed by the external controller, charger or battery life.
- implanted devices present benefits to the patient and the healthcare system in that the often invasive implantation procedures are limited. However, they pose some unique clinical risks in that the patient carries with them, either within the implant or by virtue of the implant, a much larger quantity or amount of therapy than would otherwise be prescribed by a physician, an insurer or a manufacturer.
- An implantable neurostimulator used to treat headaches can be used very frequently for the rest of the patient's lifetime. Given the unlimited nature of therapy delivered in this manner, the patient could choose to activate the neurostimulator when it is not needed. Without some limitation mechanism, the medical device may become much like an over-the-counter pharmaceutical where usage is entirely up to the user.
- a method of delivering therapy to a patient comprises checking a therapy approval status of an implanted neurostimulator on a database through an external controller, and delivering therapy from the implanted neurostimulator to the patient if the therapy approval status of the implanted neurostimulator is approved.
- therapy is not delivered from the implanted neurostimulator to the patient if the therapy approval status of the implanted neurostimulator is not approved.
- the therapy approval status of the implanted neurostimulator may not be approved if the database indicates that the implanted neurostimulator is deactivated. In other embodiments, the status of the implanted neurostimulator may not be approved if the database indicates payment is past due.
- the database is stored at a location separate from the external controller.
- the implanted neurostimulator is implanted on or near a sphenopalatine ganglion of the patient.
- the external controller is an external handheld controller.
- a list of deactivated and not approved neurostimulators on the external controller after the checking step is provided.
- a method of approving therapy in a patient comprising implanting a medical device in the patient, approving a set number of therapies to be delivered from the medical device to the patient, and deactivating the medical device when no approved therapies remain.
- the approving step further comprises approving a set number of therapies to be delivered from the medical device to the patient with a physician prescription. In other embodiments, the approving step further comprises approving a set number of therapies to be delivered from the medical device to the patient with payment by the patient.
- the method can further comprise checking a therapy approval status of the medical device with a handheld controller. In some embodiments, the method further comprises directing the medical device to deliver therapy to the patient with the handheld controller.
- the method can further comprise re-activating the medical device by approving an additional number of therapies to be delivered from the medical device to the patient.
- the method can further comprise storing a therapy approval status of the medical device on a database. In one embodiment, the method can further comprise accessing the database with a handheld controller to determine the therapy approval status of the medical device.
- the medical device is a neurostimulator.
- a system for delivering therapy to a patient comprising an implantable neurostimulator configured to deliver therapy to the patient, a database containing a therapy approval status of the implantable neurostimulator, and an external controller in communication with the database and the implantable neurostimulator, the external controller configured to direct the implantable neurostimulator to deliver therapy to the patient if the therapy approval status of the implantable neurostimulator is approved.
- the implantable neurostimulator is sized and configured to be implanted on or near a sphenopalatine ganglion.
- the external controller is a handheld controller.
- the external controller is configured to update and store a list of the therapy approval status of the implantable neurostimulator. In other embodiments, the external controller is in wireless communication with the implantable neurostimulator and the database.
- the therapy is electrical stimulation.
- the external controller is configured to deactivate the implantable stimulator if the therapy approval status of the implantable neurostimulator is not approved.
- the database is stored remotely from the implantable neurostimulator and the external controller.
- FIG. 1 shows a high level view of the neurostimulation system.
- FIG. 2 shows an embodiment of the approval per use system.
- a stimulator 1 a comprises an implantable millimeter-scale, biocompatible, hermetic electronics enclosure and integral stimulation lead system. Further details of a suitable stimulator are described in U.S. Provisional Appln. No. 61/171,749 titled “IMPLANTABLE ELECTRICAL NERVE STIMULATOR WITH INTEGRAL HERMETIC ELECTRONIC ENCLOSURE, CIRCUIT SUBSTRATE, AND MONOLITHIC FEED-THROUGH,” filed on Apr. 22, 2009.
- the stimulator can be an inductively powered system having stored programmed stimulation parameters and bi-directional telemetry to facilitate communication between the implanted neurostimulator and an external controller.
- the electronics enclosure can include an ASIC, various passive components, and a secondary coil for radio frequency transfer of power and communication.
- the integral lead system provides an electrical connection between the electronics housed in the hermetic enclosure and one or more stimulating electrodes at the distal end of the lead. Each of the one or more electrodes provides a site for electrical stimulation of the target anatomy.
- the controller 1 b can be a handheld external, rechargeable, ergonomic, energy delivery device that transfers energy to the implanted stimulator with near field electromagnetic induction.
- the controller can also be a communication system transferring information such as stimulation parameters to the implanted stimulator with bi-directional telemetry.
- the controller can receive commands from an external programmer 1 d , such as though a USB connection, for example.
- the controller can communicate with the implanted stimulator once it is within close proximity to the stimulator.
- the controller has features that allow it to deliver power along with sending commands to and receiving data from the neurostimulator.
- the controller 1 b communicates with the programmer 1 d through a USB cable connected between the controller and the programmer.
- the controller When connected to the programmer, the controller goes into a “pass through” mode in which all or some of its controls are disabled and it simply serves as a communication bridge between the PC and the stimulator.
- the controller communicates with the programmer wirelessly using WiFi, Blue Tooth, infrared or similar technology.
- the controller can include a power source such as batteries, a coil to inductively power the implant and send/receive data, a microcontroller, firmware, wireless broadband card, supporting circuitry, an ergonomically shaped housing and various manual control features such as a therapy level adjustment knob or buttons, an off/on switch, and a display.
- a power source such as batteries
- a coil to inductively power the implant and send/receive data
- a microcontroller firmware
- wireless broadband card supporting circuitry
- supporting circuitry an ergonomically shaped housing and various manual control features such as a therapy level adjustment knob or buttons, an off/on switch, and a display.
- a proprietary handshaking protocol occurs between the stimulator and the controller to ensure that only authorized devices can power up and communicate with the stimulator.
- the handshaking communication protocol ensures that only authorized devices can cause the stimulator to deliver therapy. This protects the system from situations where a user is attempting to bypass the approval system with a controller manufactured by a third party.
- the protocol could be implemented in a number of different ways including a system where the stimulator contains a coded key that is sent to the controller on power up. The key is then encrypted by the controller and sent back to the stimulator. The stimulator decrypts the key and verifies that it matches the value originally sent. If the values do not match the stimulator would deny therapy. To make breaking into the system more difficult, the stimulator could require that a certain amount of time expire before it would resend and decrypt the key again. This would help defend against “brute force” attacks where a device pretending to be a controller could send repeated versions of the key at a very rapid rate until by chance the proper value unlocks the stimulator. Any number of other handshaking security protocols could be used with the goal being that unauthorized 3 rd party controllers are denied access to the stimulator.
- the Programmer 1 d can be a PC based system used by physicians to configure stimulators that have been previously implanted in patients. It can interface with the controller 1 b wirelessly or through a USB connection to the controller. The Programmer can then instruct the controller to communicate with and receive data from the implant.
- the programmer can be used to associate patient and physician information with the serial number of the stimulator. In addition, it can also be used to program therapy settings into the stimulator. These therapy parameters include, but are not limited to, electrode configuration, stimulation amplitude, duration, and frequency. All information entered by the physician including stimulation parameters and stimulator serial number can be transferred to a central database 1 c via a wireless Internet connection on completion of the stimulator programming session. Transmission of session data can be done either via the controller or the programmer wirelessly.
- the patient can be approved for a certain number of uses of the handheld controller to apply therapy. This is analogous to being prescribed and paying for an ingestible drug on a specific dose regimen.
- Uses of the handheld controller, and hence therapy are managed by comparing patient therapy usage, activation of the implanted neurostimulator via the handheld controller, in the database with the number of approved uses for the patient.
- the approval can be any set of criteria or combinations thereof, for example but without limitation; clinical, like a physician's prescription, or financial, like pre-paid uses or an automatic payment system from stored credit card information.
- information from the database is used to allow activation of the patient's neurostimulator, via the controller, if approved uses are available. If no more approvals are available, messages can be posted to the display of the controller.
- the neurostimulator can be “turned off” or deactivated if no more approvals are intended for that patient. This can be done by wirelessly communicating with all controllers the serial numbers of implanted neurostimulators that are “OFF” or are “NOT APPROVED”.
- the database shown in step 2 a is the central repository for information relating to approval status.
- the database may be any technology that stores information and allows that information to be read and updated.
- this database can be an industry standard such as Oracle, Microsoft SQL Server, etc. and would allow standard SQL (Structured Query Language) commands to be executed against it.
- the database can comprise a table or tables that contain the serial numbers of all neurostimulators that have been implanted in patients.
- the database can also contain the approval status of these patients.
- the database can also contain billing information like credit card or bank account information, patient contact information for use in sending out notices and bills, and whether the associated stimulator should be turned ON, OFF, or if the account is NOT APPROVED.
- Middleware software shown in steps 2 b through 2 g , is the software that may run between the database and external applications such as the controller software or payment processing service, and would provide a process to read data from and write data to the database, along with logic to analyze the database and update its information accordingly.
- the database or middleware can examine the payment status of all patients. This can be done by request, by schedule, or done in real-time, for example.
- the database or middleware examines if the patients account is paid in full. If the account is paid up, then the stimulator status can be set to ON at step 2 e . If the account is not paid in full, then the database or middleware can examine if the patient's account is PAST DUE at step 2 d . If the patient's account is PAST DUE, then at step 2 f the stimulator status of PAST DUE accounts convert to OFF after a specified amount of time, delivery of therapy from the stimulator is canceled, and the patients are notified of their account status.
- the database is configured such that connections could be made directly to it and it would have the capability of updating itself when new information is available. For example, if the database lists a certain stimulator as being OFF and an approval is received, for example due to a physician's prescription or a patient payment, the database or the middleware can update the field in the database to indicate that the stimulator is now ON.
- the middleware can be either a web based or a client based application, where the client based application can be software that runs on the controller or applications associated with payment or prescription processing. Middleware may also be used to generate reports used to monitor patient trends or to improve the overall system.
- the stimulator's ability to deliver treatment is determined by the controller which checks the stimulator's serial number against its list of OFF and NOT APPROVED stimulators.
- the stimulator as described above, is “unaware” of its own of approval status and whether it should be enabled or disabled. This means that each time the stimulator is powered up by any controller it can deliver therapy if allowed by the controller regardless of approval status.
- step 2 h the patient can initiate therapy by using the handheld controller to attempt to activate the neurostimulator.
- the controller can read the serial number from the stimulator.
- step 2 j the serial number is checked against the database or middleware to determine if the stimulator status is OFF. If the status is OFF, then a warning message can be displayed to the patient at step 2 o and the stimulator does not deliver therapy at step 2 p . The message can inform the patient that approval is needed, such as by physician prescription or patient payment.
- the database or middleware is checked to see if the stimulator status is PAST DUE. If the status is PAST DUE, then a warning message can be displayed to the patient at step 2 q and the stimulator is allowed to deliver therapy at step 2 l . If the status is not PAST DUE, then the stimulator is also allowed to deliver therapy at step 2 l.
- the controller is the gateway for stimulation.
- the controller maintains a list of OFF/deactivated and NOT APPROVED stimulators and uses this list to determine if the stimulators it communicates with should be allowed to deliver therapy (see steps 2 h through 2 l and 2 o through 2 q , as described above).
- the controller's list is updated from the database via a wireless broadband transceiver built into the controller.
- the controller connects to the database (e.g., connects multiple times per day) and downloads a list of stimulators that are turned OFF or are PAST DUE. If the controller successfully connects to the database at step 2 m , then the list is updated on the controller at step 2 n.
- a warning message is displayed to the patient indicating that they must synchronize with the database or their stimulator will be disabled (see steps 2 m , 2 x , 2 aa ). After this period of time expires, subsequent attempts by the patient to initiate therapy will be denied and a warning message will be displayed on the controller indicating that the stimulator is disabled (see steps 2 m , 2 x , 2 aa , 2 bb , 2 dd , 2 cc , 2 z ). Therapy will not be delivered to this stimulator until approval is granted and an updated list indicating that the stimulator can be enabled is downloaded from the database to the controller.
- This function guards against situations where the patient either intentionally or inadvertently is outside of broadband range and the controller cannot verify approval. If a certain amount of time has not expired since the last database connection, the stimulator will attempt to reconnect to the database after a predetermined time in step 2 y.
- the patient may be granted approvals using a special numeric access key that the physician or provider enters into the controller to provide a limited number of immediate therapies. This number could also be provided to the patient via email, conventional mail, text message, website, phone, in person, or other means of communication.
- Another way of granting approval that would provide instantaneous therapy is a hardware dongle that plugs into the controller and unlocks it while the dongle is plugged in. In an alternate implementation plugging in the dongle could load a predetermined number of approvals into the controller. The dongle could then be removed and the patient could receive therapy.
- Alternate embodiments of this design include but are not limited to: Instead of downloading a list of OFF stimulators the controller might submit a direct query for information relating to the Stimulators that it specifically works with. For example if the controller works with Stimulators with serial number 11111 and 22222 it would only query the database for the status of these devices rather than the status of all stimulators that are OFF. If therapy is initiated with a stimulator the controller has not interfaced with, the controller would first attempt to look up the status of this stimulator in the database and if the database connection was successful the controller would treat the stimulator accordingly. If the connection was not successful a warning message would be displayed and treatment would be delivered but subsequent treatments would be disabled until the stimulator status can be successfully downloaded from the database.
- the patient could receive a set number of approvals for a fee.
- the controller would query the number of treatments remaining for a particular stimulator from the database and would deduct from this number each time treatment is delivered. This would require that the controller not only download the number of available treatments from the database but that it also have the ability to upload the number of treatments used to ensure proper tracking of the number of approvals remaining. This would also facilitate a system where the number of therapies available to the patient is shown as a number on the display of their controller.
- Yet another embodiment could be a system where controllers would come preset with a certain number of treatments at a set fee and when those treatments have been used up the patient would return the controller and either have it “refilled” or instead they might exchange their controller for another that is loaded with the number of treatments that are approved by the physician. Reimbursement for this could come through an insurance company, directly from the patient, or through another reimbursement source such as Medicare/Medicaid.
- Approvals for use can be generated from physician's prescriptions, analogous to being prescribed a pharmaceutical, or from patient payment analogous to a cellular phone pay-per-use billing system, or a combination thereof. Patient approvals may also be generated instantaneously in acute or emergency situations by approved providers, such as physicians or other medical personal.
- Approvals generated by physician prescription can be communicated to the Database in a number of different ways including but not limited to web-based direct programming either by existing electronic prescription systems or by a custom website or program associated with the Database, by phone using an automated system or by manual input of the approval, or automatically recurring approvals at certain time intervals analogous to refills on prescription pharmaceuticals.
- Approvals granted acutely in an emergency situation can be made as described above for physician prescriptions. Approvals may also be granted by a special numeric access key that the physician or provider enters into the controller to provide a limited number of immediate therapies.
- Another means of granting approval that would provide instantaneous therapy is a hardware dongle that plugs into the controller and unlocks it while the dongle is plugged in. In an alternate implementation plugging in the dongle could load a predetermined number of approvals into the controller. The dongle could then be removed and the patient could receive therapy.
- Approvals generated by payment can be made in a number of different ways including but not limited to credit card payments made over the web (see step 2 s ), credit card payments made over the phone (see step 2 t ), automated credit card payments (see step 2 u ), payments made from a payment vendor such as Paypal (see step 2 v ), and payments made directly from a bank account either automatically or manually.
- the system is configured to accept any form of electronic payment.
- the information for that patient is updated in the database and if the account is made current the database is updated to indicate that the patient's neurostimulator can be turned ON (see steps 2 w , 2 e , & 2 a through 2 c ) and is removed from the controller list of OFF or NOT APPROVED neurostimulators. If the prescription or the amount of payment is insufficient to bring the account current, then the database is updated to indicate that the neurostimulator should be turned OFF (see steps 2 d , 2 f , 2 g ).
- Prescription based approvals can take any number of forms, for example but without limitation, total number of uses, or time-dependent rate of uses like number of uses per day, per month or per year, or uses that expire in a defined amount of time.
- Total number of uses would be analogous to getting a prescription for one container of drugs, and would require further physician interaction to get more drugs prescribed.
- Time-dependent rate of use approval would be analogous to being prescribed a certain number of pills to be used over a certain amount of time, and after said time had elapsed the pills could be refilled.
- Other approval options may include but are not limited to pharmacist approval for a limited number of doses and immediate physician approval in an office, emergency room, or patient room setting.
- a physician may want to intervene immediately and provide approval to address an acute episode or to provide prophylactic therapy prior to a procedure.
- a number of different billing strategies can be utilized.
- a prepaid treatment based strategy where the patient would pay in advance for a certain number of treatments and this number would be decremented each time the patient used the system to deliver therapy.
- a second plan is similar to the billing system used for a cellular phone service. This plan would charge each patient a monthly fee whether they use the system for treatment or not. If the number of treatments included in the monthly fee is exceeded, then an additional fee is charged. This situation is similar to when a cellular customer exceeds the number of minutes in their monthly plan.
- a third option would be if the patient pays a large one time fee for “Product Lifetime Service.” This would allow their stimulator to be used for the lifetime of the product without further billing.
- a fourth option would be a variable plan where the patient can choose to pay by the day, the month, the year, or multiple years. Any number of other plans would work as well with the primary goal being that payment is made either on the basis of the number of times therapy is delivered or by a recurring fee that is charged regardless of whether therapies are delivered.
- the entity being billed for services is an institution rather than the individual patient.
- the patient could be removed from the billing loop and their insurance carrier, government health care provider, or other health care provider could be billed directly.
- government health care providers include but are not limited to federal organizations such as Medicare, Veterans Administration, state-sponsored programs such as Medi-Cal, and programs sponsored by counties, local governments or federal governments.
- a number of actions can be taken to notify the patient that their stimulator is about to be turned OFF. These actions might include, but are not limited to, sending emails, contact via phone, instant messages, physical letters sent via US mail, and notices sent to their controller (see step 2 g ). If a certain amount of time has expired and the patient has not made the necessary payment, the database is updated to reflect that their stimulator should be turned OFF (see step 2 f ) and their serial number will be added to the list of disabled serial numbers downloaded by each controller from the database.
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 12/688,524, filed Jan. 15, 2010, which application claims the benefit under 35 U.S.C. 119 of U.S. Provisional Patent Application No. 61/145,003, filed Jan. 15, 2009, titled “PAY PER DOSE IMPLANTED NEUROSTIMULATOR.” These applications are herein incorporated by reference in their entirety.
- All publications, including patents and patent applications, mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
- This invention is directed to an active implantable device that has features that facilitate the metered prescription of use over time, which is particularly relevant for devices that can dispense a large amount or otherwise unlimited amount of therapy without external intervention. The invention may be applied to a range of implantable medical devices including without limitation implantable drug pumps, functional electrical neurostimulators, such as spinal cord stimulators, stimulators for incontinence and deep brain stimulators. This disclosure will focus on an implantable neurostimulator used to treat headache.
- There are implantable medical devices that are loaded with or are otherwise able to administer or deliver a large or unlimited amount of therapy. For example, an implanted drug pump could contain many years worth of drug, or an inductively powered, rechargeable, or primary cell implantable stimulator could deliver therapy in perpetuity as governed by the external controller, charger or battery life. These types of implanted devices present benefits to the patient and the healthcare system in that the often invasive implantation procedures are limited. However, they pose some unique clinical risks in that the patient carries with them, either within the implant or by virtue of the implant, a much larger quantity or amount of therapy than would otherwise be prescribed by a physician, an insurer or a manufacturer.
- An implantable neurostimulator used to treat headaches can be used very frequently for the rest of the patient's lifetime. Given the unlimited nature of therapy delivered in this manner, the patient could choose to activate the neurostimulator when it is not needed. Without some limitation mechanism, the medical device may become much like an over-the-counter pharmaceutical where usage is entirely up to the user.
- The inability to limit use of such medical devices poses potential clinical risks to the patient, such as over-use (if over use is a clinical problem) that leads to ineffective therapy over time at therapy levels that were once effective. The absence of usage limits may also fatigue the internal components of the device, resulting in a shorter therapeutic lifetime. Further, it can pose increased financial burden to the healthcare system due to poorer clinical outcomes or more frequent device failures. Finally, it can also present financial constraints on patients, for example if the device is priced based on all potential uses of the device, or constraints on an insurer or the manufacturer if patients use the device much more than intended.
- A method of delivering therapy to a patient comprises checking a therapy approval status of an implanted neurostimulator on a database through an external controller, and delivering therapy from the implanted neurostimulator to the patient if the therapy approval status of the implanted neurostimulator is approved.
- In some embodiments, therapy is not delivered from the implanted neurostimulator to the patient if the therapy approval status of the implanted neurostimulator is not approved. In one embodiment, the therapy approval status of the implanted neurostimulator may not be approved if the database indicates that the implanted neurostimulator is deactivated. In other embodiments, the status of the implanted neurostimulator may not be approved if the database indicates payment is past due.
- In some embodiments, the database is stored at a location separate from the external controller.
- In one embodiment, the implanted neurostimulator is implanted on or near a sphenopalatine ganglion of the patient.
- In some embodiments, the external controller is an external handheld controller.
- In one embodiment, a list of deactivated and not approved neurostimulators on the external controller after the checking step.
- A method of approving therapy in a patient is provided, comprising implanting a medical device in the patient, approving a set number of therapies to be delivered from the medical device to the patient, and deactivating the medical device when no approved therapies remain.
- In some embodiments, the approving step further comprises approving a set number of therapies to be delivered from the medical device to the patient with a physician prescription. In other embodiments, the approving step further comprises approving a set number of therapies to be delivered from the medical device to the patient with payment by the patient.
- The method can further comprise checking a therapy approval status of the medical device with a handheld controller. In some embodiments, the method further comprises directing the medical device to deliver therapy to the patient with the handheld controller.
- In one embodiment, the method can further comprise re-activating the medical device by approving an additional number of therapies to be delivered from the medical device to the patient.
- In another embodiment, the method can further comprise storing a therapy approval status of the medical device on a database. In one embodiment, the method can further comprise accessing the database with a handheld controller to determine the therapy approval status of the medical device.
- In some embodiments, the medical device is a neurostimulator.
- A system for delivering therapy to a patient is also provided, comprising an implantable neurostimulator configured to deliver therapy to the patient, a database containing a therapy approval status of the implantable neurostimulator, and an external controller in communication with the database and the implantable neurostimulator, the external controller configured to direct the implantable neurostimulator to deliver therapy to the patient if the therapy approval status of the implantable neurostimulator is approved.
- In some embodiments, the implantable neurostimulator is sized and configured to be implanted on or near a sphenopalatine ganglion.
- In one embodiment, the external controller is a handheld controller.
- In some embodiments, the external controller is configured to update and store a list of the therapy approval status of the implantable neurostimulator. In other embodiments, the external controller is in wireless communication with the implantable neurostimulator and the database.
- In some embodiments, the therapy is electrical stimulation.
- In other embodiments, the external controller is configured to deactivate the implantable stimulator if the therapy approval status of the implantable neurostimulator is not approved.
- In some embodiments, the database is stored remotely from the implantable neurostimulator and the external controller.
-
FIG. 1 shows a high level view of the neurostimulation system. -
FIG. 2 shows an embodiment of the approval per use system. - Referring to
FIG. 1 , astimulator 1 a comprises an implantable millimeter-scale, biocompatible, hermetic electronics enclosure and integral stimulation lead system. Further details of a suitable stimulator are described in U.S. Provisional Appln. No. 61/171,749 titled “IMPLANTABLE ELECTRICAL NERVE STIMULATOR WITH INTEGRAL HERMETIC ELECTRONIC ENCLOSURE, CIRCUIT SUBSTRATE, AND MONOLITHIC FEED-THROUGH,” filed on Apr. 22, 2009. The stimulator can be an inductively powered system having stored programmed stimulation parameters and bi-directional telemetry to facilitate communication between the implanted neurostimulator and an external controller. The electronics enclosure can include an ASIC, various passive components, and a secondary coil for radio frequency transfer of power and communication. The integral lead system provides an electrical connection between the electronics housed in the hermetic enclosure and one or more stimulating electrodes at the distal end of the lead. Each of the one or more electrodes provides a site for electrical stimulation of the target anatomy. - The
controller 1 b can be a handheld external, rechargeable, ergonomic, energy delivery device that transfers energy to the implanted stimulator with near field electromagnetic induction. The controller can also be a communication system transferring information such as stimulation parameters to the implanted stimulator with bi-directional telemetry. The controller can receive commands from anexternal programmer 1 d, such as though a USB connection, for example. The controller can communicate with the implanted stimulator once it is within close proximity to the stimulator. In one embodiment the controller has features that allow it to deliver power along with sending commands to and receiving data from the neurostimulator. - In one embodiment, the
controller 1 b communicates with theprogrammer 1 d through a USB cable connected between the controller and the programmer. When connected to the programmer, the controller goes into a “pass through” mode in which all or some of its controls are disabled and it simply serves as a communication bridge between the PC and the stimulator. - In an alternate embodiment, the controller communicates with the programmer wirelessly using WiFi, Blue Tooth, infrared or similar technology.
- The controller can include a power source such as batteries, a coil to inductively power the implant and send/receive data, a microcontroller, firmware, wireless broadband card, supporting circuitry, an ergonomically shaped housing and various manual control features such as a therapy level adjustment knob or buttons, an off/on switch, and a display.
- In one embodiment, a proprietary handshaking protocol occurs between the stimulator and the controller to ensure that only authorized devices can power up and communicate with the stimulator. The handshaking communication protocol ensures that only authorized devices can cause the stimulator to deliver therapy. This protects the system from situations where a user is attempting to bypass the approval system with a controller manufactured by a third party.
- The protocol could be implemented in a number of different ways including a system where the stimulator contains a coded key that is sent to the controller on power up. The key is then encrypted by the controller and sent back to the stimulator. The stimulator decrypts the key and verifies that it matches the value originally sent. If the values do not match the stimulator would deny therapy. To make breaking into the system more difficult, the stimulator could require that a certain amount of time expire before it would resend and decrypt the key again. This would help defend against “brute force” attacks where a device pretending to be a controller could send repeated versions of the key at a very rapid rate until by chance the proper value unlocks the stimulator. Any number of other handshaking security protocols could be used with the goal being that unauthorized 3rd party controllers are denied access to the stimulator.
- The
Programmer 1 d can be a PC based system used by physicians to configure stimulators that have been previously implanted in patients. It can interface with thecontroller 1 b wirelessly or through a USB connection to the controller. The Programmer can then instruct the controller to communicate with and receive data from the implant. The programmer can be used to associate patient and physician information with the serial number of the stimulator. In addition, it can also be used to program therapy settings into the stimulator. These therapy parameters include, but are not limited to, electrode configuration, stimulation amplitude, duration, and frequency. All information entered by the physician including stimulation parameters and stimulator serial number can be transferred to acentral database 1 c via a wireless Internet connection on completion of the stimulator programming session. Transmission of session data can be done either via the controller or the programmer wirelessly. - In the flowchart diagram shown in
FIG. 2 , the patient can be approved for a certain number of uses of the handheld controller to apply therapy. This is analogous to being prescribed and paying for an ingestible drug on a specific dose regimen. Uses of the handheld controller, and hence therapy, are managed by comparing patient therapy usage, activation of the implanted neurostimulator via the handheld controller, in the database with the number of approved uses for the patient. The approval can be any set of criteria or combinations thereof, for example but without limitation; clinical, like a physician's prescription, or financial, like pre-paid uses or an automatic payment system from stored credit card information. - For the system to work, information from the database is used to allow activation of the patient's neurostimulator, via the controller, if approved uses are available. If no more approvals are available, messages can be posted to the display of the controller. The neurostimulator can be “turned off” or deactivated if no more approvals are intended for that patient. This can be done by wirelessly communicating with all controllers the serial numbers of implanted neurostimulators that are “OFF” or are “NOT APPROVED”.
- In
FIG. 2 , the database shown instep 2 a is the central repository for information relating to approval status. The database may be any technology that stores information and allows that information to be read and updated. In one embodiment, this database can be an industry standard such as Oracle, Microsoft SQL Server, etc. and would allow standard SQL (Structured Query Language) commands to be executed against it. The database can comprise a table or tables that contain the serial numbers of all neurostimulators that have been implanted in patients. The database can also contain the approval status of these patients. For example, if there are no remaining physician-prescribed uses, or if the patient is delinquent in payment then the patient approval status can be set to “NOT APPROVED.” The database can also contain billing information like credit card or bank account information, patient contact information for use in sending out notices and bills, and whether the associated stimulator should be turned ON, OFF, or if the account is NOT APPROVED. - Middleware software, shown in
steps 2 b through 2 g, is the software that may run between the database and external applications such as the controller software or payment processing service, and would provide a process to read data from and write data to the database, along with logic to analyze the database and update its information accordingly. - For example, referring to
steps 2 b through 2 g, atstep 2 b the database or middleware can examine the payment status of all patients. This can be done by request, by schedule, or done in real-time, for example. Atstep 2 c, the database or middleware examines if the patients account is paid in full. If the account is paid up, then the stimulator status can be set to ON atstep 2 e. If the account is not paid in full, then the database or middleware can examine if the patient's account is PAST DUE atstep 2 d. If the patient's account is PAST DUE, then atstep 2 f the stimulator status of PAST DUE accounts convert to OFF after a specified amount of time, delivery of therapy from the stimulator is canceled, and the patients are notified of their account status. - In an alternate embodiment, the database is configured such that connections could be made directly to it and it would have the capability of updating itself when new information is available. For example, if the database lists a certain stimulator as being OFF and an approval is received, for example due to a physician's prescription or a patient payment, the database or the middleware can update the field in the database to indicate that the stimulator is now ON.
- The middleware can be either a web based or a client based application, where the client based application can be software that runs on the controller or applications associated with payment or prescription processing. Middleware may also be used to generate reports used to monitor patient trends or to improve the overall system.
- Upon being powered up, the stimulator's ability to deliver treatment is determined by the controller which checks the stimulator's serial number against its list of OFF and NOT APPROVED stimulators. The stimulator, as described above, is “unaware” of its own of approval status and whether it should be enabled or disabled. This means that each time the stimulator is powered up by any controller it can deliver therapy if allowed by the controller regardless of approval status.
- A method of approving the use of an implanted neurostimulator, and hence therapy, will now be described. Referring to
steps 2 h through 2 l and 2 o through 2 q, atstep 2 h the patient can initiate therapy by using the handheld controller to attempt to activate the neurostimulator. Atstep 2 i, the controller can read the serial number from the stimulator. Atstep 2 j, the serial number is checked against the database or middleware to determine if the stimulator status is OFF. If the status is OFF, then a warning message can be displayed to the patient at step 2 o and the stimulator does not deliver therapy atstep 2 p. The message can inform the patient that approval is needed, such as by physician prescription or patient payment. Alternatively, if the stimulator status is not OFF, then the database or middleware is checked to see if the stimulator status is PAST DUE. If the status is PAST DUE, then a warning message can be displayed to the patient atstep 2 q and the stimulator is allowed to deliver therapy at step 2 l. If the status is not PAST DUE, then the stimulator is also allowed to deliver therapy at step 2 l. - The controller, as described above, is the gateway for stimulation. The controller maintains a list of OFF/deactivated and NOT APPROVED stimulators and uses this list to determine if the stimulators it communicates with should be allowed to deliver therapy (see
steps 2 h through 2 l and 2 o through 2 q, as described above). - The controller's list is updated from the database via a wireless broadband transceiver built into the controller. Referring to step 2 r, the controller connects to the database (e.g., connects multiple times per day) and downloads a list of stimulators that are turned OFF or are PAST DUE. If the controller successfully connects to the database at
step 2 m, then the list is updated on the controller atstep 2 n. - If the controller is unable to update its list of stimulators from the database for an extended period of time, a warning message is displayed to the patient indicating that they must synchronize with the database or their stimulator will be disabled (see
steps steps step 2 y. - If the patient does not live in an area that supports broadband access that would allow them to receive approvals the patient may be granted approvals using a special numeric access key that the physician or provider enters into the controller to provide a limited number of immediate therapies. This number could also be provided to the patient via email, conventional mail, text message, website, phone, in person, or other means of communication. Another way of granting approval that would provide instantaneous therapy is a hardware dongle that plugs into the controller and unlocks it while the dongle is plugged in. In an alternate implementation plugging in the dongle could load a predetermined number of approvals into the controller. The dongle could then be removed and the patient could receive therapy.
- Alternate embodiments of this design include but are not limited to: Instead of downloading a list of OFF stimulators the controller might submit a direct query for information relating to the Stimulators that it specifically works with. For example if the controller works with Stimulators with serial number 11111 and 22222 it would only query the database for the status of these devices rather than the status of all stimulators that are OFF. If therapy is initiated with a stimulator the controller has not interfaced with, the controller would first attempt to look up the status of this stimulator in the database and if the database connection was successful the controller would treat the stimulator accordingly. If the connection was not successful a warning message would be displayed and treatment would be delivered but subsequent treatments would be disabled until the stimulator status can be successfully downloaded from the database.
- In another embodiment, instead of using a list of OFF stimulators to determine which stimulators can deliver therapy the patient could receive a set number of approvals for a fee. In this method the controller would query the number of treatments remaining for a particular stimulator from the database and would deduct from this number each time treatment is delivered. This would require that the controller not only download the number of available treatments from the database but that it also have the ability to upload the number of treatments used to ensure proper tracking of the number of approvals remaining. This would also facilitate a system where the number of therapies available to the patient is shown as a number on the display of their controller.
- Yet another embodiment could be a system where controllers would come preset with a certain number of treatments at a set fee and when those treatments have been used up the patient would return the controller and either have it “refilled” or instead they might exchange their controller for another that is loaded with the number of treatments that are approved by the physician. Reimbursement for this could come through an insurance company, directly from the patient, or through another reimbursement source such as Medicare/Medicaid.
- Approvals for use can be generated from physician's prescriptions, analogous to being prescribed a pharmaceutical, or from patient payment analogous to a cellular phone pay-per-use billing system, or a combination thereof. Patient approvals may also be generated instantaneously in acute or emergency situations by approved providers, such as physicians or other medical personal.
- Approvals generated by physician prescription can be communicated to the Database in a number of different ways including but not limited to web-based direct programming either by existing electronic prescription systems or by a custom website or program associated with the Database, by phone using an automated system or by manual input of the approval, or automatically recurring approvals at certain time intervals analogous to refills on prescription pharmaceuticals.
- Approvals granted acutely in an emergency situation can be made as described above for physician prescriptions. Approvals may also be granted by a special numeric access key that the physician or provider enters into the controller to provide a limited number of immediate therapies. Another means of granting approval that would provide instantaneous therapy is a hardware dongle that plugs into the controller and unlocks it while the dongle is plugged in. In an alternate implementation plugging in the dongle could load a predetermined number of approvals into the controller. The dongle could then be removed and the patient could receive therapy.
- Approvals generated by payment can be made in a number of different ways including but not limited to credit card payments made over the web (see
step 2 s), credit card payments made over the phone (seestep 2 t), automated credit card payments (seestep 2 u), payments made from a payment vendor such as Paypal (seestep 2 v), and payments made directly from a bank account either automatically or manually. The system is configured to accept any form of electronic payment. - Once approval is granted, the information for that patient is updated in the database and if the account is made current the database is updated to indicate that the patient's neurostimulator can be turned ON (see
steps steps - Prescription based approvals can take any number of forms, for example but without limitation, total number of uses, or time-dependent rate of uses like number of uses per day, per month or per year, or uses that expire in a defined amount of time. Total number of uses would be analogous to getting a prescription for one container of drugs, and would require further physician interaction to get more drugs prescribed. Time-dependent rate of use approval would be analogous to being prescribed a certain number of pills to be used over a certain amount of time, and after said time had elapsed the pills could be refilled.
- There are types of physician prescription approval schemes for which no pharmaceutical analogy exists too. For example, in the case of a neurostimulator to treat headache, it may be undesirable to activate the device too frequently as described previously.
- Other approval options may include but are not limited to pharmacist approval for a limited number of doses and immediate physician approval in an office, emergency room, or patient room setting.
- In the case of pharmacist approval a patient may have forgotten to contact their physician or other provider to renew their prescription or perhaps their physician is out of town. As with prescription medications a pharmacist may at their discretion provide a limited number of doses to the patient.
- In the hospital setting a physician may want to intervene immediately and provide approval to address an acute episode or to provide prophylactic therapy prior to a procedure.
- For payment based approvals, a number of different billing strategies can be utilized. A prepaid treatment based strategy where the patient would pay in advance for a certain number of treatments and this number would be decremented each time the patient used the system to deliver therapy.
- A second plan is similar to the billing system used for a cellular phone service. This plan would charge each patient a monthly fee whether they use the system for treatment or not. If the number of treatments included in the monthly fee is exceeded, then an additional fee is charged. This situation is similar to when a cellular customer exceeds the number of minutes in their monthly plan.
- A third option would be if the patient pays a large one time fee for “Product Lifetime Service.” This would allow their stimulator to be used for the lifetime of the product without further billing. A fourth option would be a variable plan where the patient can choose to pay by the day, the month, the year, or multiple years. Any number of other plans would work as well with the primary goal being that payment is made either on the basis of the number of times therapy is delivered or by a recurring fee that is charged regardless of whether therapies are delivered.
- It is also possible that the entity being billed for services is an institution rather than the individual patient. In this scenario the patient could be removed from the billing loop and their insurance carrier, government health care provider, or other health care provider could be billed directly. Examples of government health care providers include but are not limited to federal organizations such as Medicare, Veterans Administration, state-sponsored programs such as Medi-Cal, and programs sponsored by counties, local governments or federal governments.
- If the patient is being billed directly and it is determined that their account is past due, a number of actions can be taken to notify the patient that their stimulator is about to be turned OFF. These actions might include, but are not limited to, sending emails, contact via phone, instant messages, physical letters sent via US mail, and notices sent to their controller (see
step 2 g). If a certain amount of time has expired and the patient has not made the necessary payment, the database is updated to reflect that their stimulator should be turned OFF (seestep 2 f) and their serial number will be added to the list of disabled serial numbers downloaded by each controller from the database. - If an entity, like and insurance carrier, is being billed there could be two tiers of notification: The first being that the provider is notified by the means described in the prior paragraph or by representatives from the device manufacturer; and the second being that if the entity has failed to provide payment the patient is notified that they need to take action to keep their account current.
- As for additional details pertinent to the present invention, materials and manufacturing techniques may be employed as within the level of those with skill in the relevant art. The same may hold true with respect to method-based aspects of the invention in terms of additional acts commonly or logically employed. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Likewise, reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “and,” “said,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The breadth of the present invention is not to be limited by the subject specification, but rather only by the plain meaning of the claim terms employed.
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/849,351 US20150374998A1 (en) | 2009-01-15 | 2015-09-09 | Approval per use implanted neurostimulator |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14500309P | 2009-01-15 | 2009-01-15 | |
US12/688,524 US9320908B2 (en) | 2009-01-15 | 2010-01-15 | Approval per use implanted neurostimulator |
US14/849,351 US20150374998A1 (en) | 2009-01-15 | 2015-09-09 | Approval per use implanted neurostimulator |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/688,524 Continuation US9320908B2 (en) | 2009-01-15 | 2010-01-15 | Approval per use implanted neurostimulator |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150374998A1 true US20150374998A1 (en) | 2015-12-31 |
Family
ID=42319610
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/688,524 Active 2032-04-17 US9320908B2 (en) | 2009-01-15 | 2010-01-15 | Approval per use implanted neurostimulator |
US14/849,351 Abandoned US20150374998A1 (en) | 2009-01-15 | 2015-09-09 | Approval per use implanted neurostimulator |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/688,524 Active 2032-04-17 US9320908B2 (en) | 2009-01-15 | 2010-01-15 | Approval per use implanted neurostimulator |
Country Status (1)
Country | Link |
---|---|
US (2) | US9320908B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9643022B2 (en) | 2013-06-17 | 2017-05-09 | Nyxoah SA | Flexible control housing for disposable patch |
US9849289B2 (en) | 2009-10-20 | 2017-12-26 | Nyxoah SA | Device and method for snoring detection and control |
US9855032B2 (en) | 2012-07-26 | 2018-01-02 | Nyxoah SA | Transcutaneous power conveyance device |
US9943686B2 (en) | 2009-10-20 | 2018-04-17 | Nyxoah SA | Method and device for treating sleep apnea based on tongue movement |
US10052097B2 (en) | 2012-07-26 | 2018-08-21 | Nyxoah SA | Implant unit delivery tool |
US10751537B2 (en) | 2009-10-20 | 2020-08-25 | Nyxoah SA | Arced implant unit for modulation of nerves |
US10814137B2 (en) | 2012-07-26 | 2020-10-27 | Nyxoah SA | Transcutaneous power conveyance device |
US11253712B2 (en) | 2012-07-26 | 2022-02-22 | Nyxoah SA | Sleep disordered breathing treatment apparatus |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US8412336B2 (en) | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
US20130110195A1 (en) | 2009-01-15 | 2013-05-02 | Autonomic Technologies, Inc. | Neurostimulator system, apparatus, and method |
US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
US20130116745A1 (en) * | 2009-01-15 | 2013-05-09 | Autonomic Technologies, Inc. | Neurostimulator system, apparatus, and method |
US11581090B2 (en) * | 2017-12-22 | 2023-02-14 | Electrocore, Inc. | Technologies for initial provisioning and refilling of medical devices |
AU2012271480B2 (en) * | 2011-06-16 | 2016-07-14 | Advanced Uro-Solutions, Llc | Percutaneous tibial nerve stimulator |
DE102011118671A1 (en) * | 2011-11-16 | 2013-05-16 | Cerbomed Gmbh | System for use in pinna of ear for transcutaneous stimulation of vagus nerve of human body, has establishing unit establishing data connection between central computer and local computer, where central computer comprises data memory |
US20150018728A1 (en) | 2012-01-26 | 2015-01-15 | Bluewind Medical Ltd. | Wireless neurostimulators |
US9020601B2 (en) * | 2012-07-23 | 2015-04-28 | Cochlear Limited | Hearing prosthesis with a standard wire interface |
CN110251839A (en) * | 2012-09-10 | 2019-09-20 | 真皮光子公司 | The medical device of dermatology |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US20160117452A1 (en) * | 2013-06-07 | 2016-04-28 | Brainique Ag | Systems and methods for prescriptions for noninvasive electrical brain stimulation |
US20160336813A1 (en) | 2015-05-15 | 2016-11-17 | NeuSpera Medical Inc. | Midfield coupler |
US11229394B2 (en) * | 2015-08-11 | 2022-01-25 | Inspire Medical Systems, Inc. | Platform for secure communications with medical device |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
CN116785591A (en) * | 2023-06-25 | 2023-09-22 | 北京领创医谷科技发展有限责任公司 | Method and device for initially binding energy controller and stimulator in operation and electronic equipment |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080021341A1 (en) * | 2006-06-23 | 2008-01-24 | Neurovista Corporation A Delware Corporation | Methods and Systems for Facilitating Clinical Trials |
US20080221921A1 (en) * | 2007-01-19 | 2008-09-11 | Ventrassist Pty Ltd | Method of conducting a clinical trial |
US20100211123A1 (en) * | 2009-02-19 | 2010-08-19 | Stubbs Scott R | Systems and methods for providing arrhythmia therapy in mri environments |
US20110125214A1 (en) * | 2009-11-25 | 2011-05-26 | Medtronic, Inc. | Medical electrical stimulation with external simulated case electrode |
US8055347B2 (en) * | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8165691B2 (en) * | 2009-10-19 | 2012-04-24 | Medtronic, Inc. | Implantable medical device with selectively configurable exposure operating mode programming options |
US20120302912A1 (en) * | 2011-05-27 | 2012-11-29 | Boston Scientific Neuromodulation Corporation | Collection of clinical data for graphical representation and analysis |
Family Cites Families (313)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2123980A (en) | 1934-07-21 | 1938-07-19 | G M Basford Company | Therapeutic treatment |
US2182071A (en) | 1937-08-12 | 1939-12-05 | Johnson Lab Inc | Adjustable coupling system |
US3357434A (en) | 1964-04-06 | 1967-12-12 | Avco Corp | Inductively linked receiver |
US3746004A (en) | 1971-06-14 | 1973-07-17 | B Jankelson | Disposable electrodes for electrical stimulation of muscles and nerves of the head |
US3862321A (en) | 1971-07-19 | 1975-01-21 | Astra Pharma Prod | Acyl xylidide local anaesthetics |
US3925469A (en) | 1972-02-28 | 1975-12-09 | Astra Pharma Prod | Tetiary-alkylamino-lower-acyl-xylidide local anaesthetics |
US3859103A (en) | 1973-03-08 | 1975-01-07 | Nippon Selfoc Co Ltd | Optical glass body having a refractive index gradient |
US3914283A (en) | 1973-12-10 | 1975-10-21 | Hoffmann La Roche | Polymeric local anesthetic and anti-arrhythmic agents |
US3923060A (en) | 1974-04-23 | 1975-12-02 | Jr Everett H Ellinwood | Apparatus and method for implanted self-powered medication dispensing having timing and evaluator means |
US4217349A (en) | 1974-07-01 | 1980-08-12 | Sumitomo Chemical Company, Limited | Benzisoxazole derivatives |
SE399419B (en) | 1974-12-20 | 1978-02-13 | Astra Laekemedel Ab | ANALOGICAL PROCEDURE FOR PRODUCTION OF NEW LOCAL ANESTHETIC ASSOCIATIONS |
US4147804A (en) | 1975-03-31 | 1979-04-03 | William H. Rorer, Inc. | Amidinourea local anesthetics |
CH602581A5 (en) | 1976-07-19 | 1978-07-31 | Cermol Sa | |
US4102344A (en) | 1976-11-15 | 1978-07-25 | Mentor Corporation | Stimulator apparatus for internal body organ |
SE7713618L (en) | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | LOCAL ANESTHETIC MIXTURE |
US4379161A (en) | 1979-06-07 | 1983-04-05 | Michel Thominet | Novel substituted heterocyclic phenoxyamines, the method of preparation thereof and the use thereof as local anaesthetics |
US4305402A (en) | 1979-06-29 | 1981-12-15 | Katims Jefferson J | Method for transcutaneous electrical stimulation |
US4298603A (en) | 1979-12-06 | 1981-11-03 | Industrial Technology Research Institute | O-Aminoalkylsalicylates |
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4565200A (en) | 1980-09-24 | 1986-01-21 | Cosman Eric R | Universal lesion and recording electrode system |
US4352820A (en) | 1980-12-11 | 1982-10-05 | Virginia Mason Research Center | Method for providing long-lasting local anesthesia and compounds and compositions therefore |
BE889540A (en) | 1981-07-08 | 1982-01-08 | Herstal Sa | STEREOTAXIC DEVICE FOR ELECTROCOAGULATION OF GASSER GANGLIONS |
US4441210A (en) | 1981-09-18 | 1984-04-03 | Hochmair Erwin S | Transcutaneous signal transmission system and methods |
US4397845A (en) | 1982-05-19 | 1983-08-09 | The Upjohn Company | Lincomycin 3-(5'-adenylate) as anesthetic |
IT1152487B (en) | 1982-08-06 | 1986-12-31 | Baldacci Lab Spa | 2- (OMEGA-ALCHILAMINOALCHIL) -E 2- (OMEGA-DIALKILAMINOALCHIL) -3 - - (4 -X-BENZYLIDENE) FTALIMIDINE, PROCEDURE FOR THEIR PREPARATION AND USE |
US4495174A (en) | 1982-06-21 | 1985-01-22 | Research Corporation | Anesthetic polyorganophosphazenes |
US4519400A (en) | 1983-04-01 | 1985-05-28 | Biosonics, Inc. | Method for stimulating salivation |
US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
US4871475A (en) | 1985-10-07 | 1989-10-03 | The Boeing Company | Polysulfone and polyethersulfone oligomers |
DE3379266D1 (en) | 1983-08-01 | 1989-04-06 | Astra Laekemedel Ab | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
IT1164387B (en) | 1983-08-05 | 1987-04-08 | Zambon Spa | N-SUBSTITUTED DERIVATIVES OF 1- (4'-ALCHILSULFONILFENIL) -2-AMINO-1,3-PROPANDIOL |
US4550733A (en) | 1984-01-09 | 1985-11-05 | Pain Suppression Labs, Inc. | Electronic dental analgesia apparatus and methodology |
US4784142A (en) | 1984-01-09 | 1988-11-15 | Pain Suppression Labs, Inc. | Methodology for electronic dental analgesia |
US4627438A (en) | 1984-01-09 | 1986-12-09 | Pain Suppression Labs, Inc. | Electronic migraine modulator apparatus and methodology |
US4856526A (en) | 1984-01-09 | 1989-08-15 | Pain Suppression Labs, Inc. | Apparatus and methodology for treatment of headache syndromes |
US4646744A (en) | 1984-06-29 | 1987-03-03 | Zion Foundation | Method and treatment with transcranially applied electrical signals |
US4695576A (en) | 1984-07-09 | 1987-09-22 | Astra Lake Medel Aktiebolag | L-N-n-propylpipecolic acid-2,6-xylidide |
US4592359A (en) | 1985-04-02 | 1986-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-channel implantable neural stimulator |
AT385894B (en) | 1985-10-04 | 1988-05-25 | Basem Dr Nashef | TUBULAR PROBE |
SE451840B (en) | 1986-01-03 | 1987-11-02 | Astra Laekemedel Ab | OPTICALLY PURE MONOHYDRATED OF S - (-) - 1-PROPYL-2 ', 6'-PIPECOLOXYLIDE HYDROCHLORIDE, SET TO PREPARE THIS AND PHARMACEUTICAL PREPARATIONS FOR LOCAL ANCHORING |
US4727145A (en) | 1986-09-22 | 1988-02-23 | Ortho Pharmaceutical Corporation | 2- Or 3- aryl substituted imidazo [1,2-a]pyridines |
US4833149A (en) | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
US4718423A (en) | 1986-10-17 | 1988-01-12 | Spectramed, Inc. | Multiple-function cardiovascular catheter system with very high lumenal efficiency and no crossovers |
SE8605515D0 (en) | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE |
US5387587A (en) | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
US4830008A (en) | 1987-04-24 | 1989-05-16 | Meer Jeffrey A | Method and system for treatment of sleep apnea |
US4886493A (en) | 1987-10-22 | 1989-12-12 | Jordan Yee | Medical applicator process |
US5038781A (en) | 1988-01-21 | 1991-08-13 | Hassan Hamedi | Multi-electrode neurological stimulation apparatus |
US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4937078A (en) | 1988-08-26 | 1990-06-26 | Mezei Associates Limited | Liposomal local anesthetic and analgesic products |
US4920979A (en) | 1988-10-12 | 1990-05-01 | Huntington Medical Research Institute | Bidirectional helical electrode for nerve stimulation |
US5458631A (en) | 1989-01-06 | 1995-10-17 | Xavier; Ravi | Implantable catheter with electrical pulse nerve stimulators and drug delivery system |
US4976711A (en) | 1989-04-13 | 1990-12-11 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
JP2794196B2 (en) | 1989-06-20 | 1998-09-03 | チェスト株式会社 | Apnea prevention stimulator |
US5227165A (en) | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
SE8904298D0 (en) | 1989-12-21 | 1989-12-21 | Astra Ab | NEW COMPOUNDS |
US5420151A (en) | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
EP0532546B1 (en) | 1990-05-10 | 1998-03-18 | Bechgaard International Research And Development A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
US5314458A (en) | 1990-06-01 | 1994-05-24 | University Of Michigan | Single channel microstimulator |
WO1992007605A1 (en) | 1990-11-05 | 1992-05-14 | Ravi Xavier | Implantable drug dispensing multielectrode catheter |
US5676955A (en) | 1990-11-09 | 1997-10-14 | Henkel Kommanditgesellschaft Auf Aktien | Local anesthetic |
US5199428A (en) | 1991-03-22 | 1993-04-06 | Medtronic, Inc. | Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload |
US5215086A (en) | 1991-05-03 | 1993-06-01 | Cyberonics, Inc. | Therapeutic treatment of migraine symptoms by stimulation |
US5335657A (en) | 1991-05-03 | 1994-08-09 | Cyberonics, Inc. | Therapeutic treatment of sleep disorder by nerve stimulation |
US5259387A (en) | 1991-09-09 | 1993-11-09 | Quinton Instrument Company | ECG muscle artifact filter system |
US5318592A (en) | 1991-09-12 | 1994-06-07 | BIOTRONIK, Mess- und Therapiegerate GmbH & Co., Ingenieurburo Berlin | Cardiac therapy system |
US5255691A (en) | 1991-11-13 | 1993-10-26 | Medtronic, Inc. | Percutaneous epidural lead introducing system and method |
CA2083686C (en) | 1991-11-27 | 2001-08-21 | Ross G. Stone | Tension headache reliever |
US5193539A (en) | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Implantable microstimulator |
IT1259358B (en) | 1992-03-26 | 1996-03-12 | Sorin Biomedica Spa | IMPLANTABLE DEVICE FOR DETECTION AND CONTROL OF THE SYMPATHIC-VAGAL TONE |
US5330515A (en) | 1992-06-17 | 1994-07-19 | Cyberonics, Inc. | Treatment of pain by vagal afferent stimulation |
US5514131A (en) | 1992-08-12 | 1996-05-07 | Stuart D. Edwards | Method for the ablation treatment of the uvula |
SE9203733D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | defibrillation |
US5344438A (en) | 1993-04-16 | 1994-09-06 | Medtronic, Inc. | Cuff electrode |
DK80593D0 (en) | 1993-07-06 | 1993-07-06 | Scanvaegt As | PROCEDURES AND PLACES FOR WEIGHTING OBJECTIVES |
US5490520A (en) | 1993-09-27 | 1996-02-13 | Schaefer Partnership | Dental applicance for treating bruxism |
SE9303281D0 (en) | 1993-10-07 | 1993-10-07 | Astra Ab | New formulation |
US5433739A (en) | 1993-11-02 | 1995-07-18 | Sluijter; Menno E. | Method and apparatus for heating an intervertebral disc for relief of back pain |
US5458626A (en) | 1993-12-27 | 1995-10-17 | Krause; Horst E. | Method of electrical nerve stimulation for acceleration of tissue healing |
SE9400447D0 (en) | 1994-02-11 | 1994-02-11 | Astra Ab | New compounds |
US5571159A (en) | 1994-04-04 | 1996-11-05 | Alt; Eckhard | Temporary atrial defibrillation catheter and method |
SE9401174D0 (en) | 1994-04-07 | 1994-04-07 | Astra Ab | New combination |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US5843021A (en) | 1994-05-09 | 1998-12-01 | Somnus Medical Technologies, Inc. | Cell necrosis apparatus |
EP0688579B1 (en) | 1994-06-24 | 2001-08-22 | St. Jude Medical AB | Device for heart therapy |
EP0688578B1 (en) | 1994-06-24 | 1999-11-10 | Pacesetter AB | Arrhythmia detector |
US5558622A (en) | 1994-09-02 | 1996-09-24 | Greenberg Surgical Technologies, Llc | Mandibular border retractor and method for fixating a fractured mandible |
US5540734A (en) | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5560351A (en) | 1994-10-07 | 1996-10-01 | University Of Florida | Transtracheal energy application and sensing system for intubation: method and apparatus |
AUPM982694A0 (en) | 1994-12-02 | 1995-01-05 | University Of Queensland, The | Iontophoresis method and apparatus |
US5545219A (en) | 1995-03-30 | 1996-08-13 | Cochlear, Ltd. | Cochlear electrode implant assemblies with positioning system therefor |
US5591216A (en) | 1995-05-19 | 1997-01-07 | Medtronic, Inc. | Method for treatment of sleep apnea by electrical stimulation |
US5735817A (en) | 1995-05-19 | 1998-04-07 | Shantha; T. R. | Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures |
US5640764A (en) | 1995-05-22 | 1997-06-24 | Alfred E. Mann Foundation For Scientific Research | Method of forming a tubular feed-through hermetic seal for an implantable medical device |
RU2108817C1 (en) | 1995-05-22 | 1998-04-20 | Карашуров Сергей Егорович | Method for treating the cases of bronchial asthma |
US5540730A (en) | 1995-06-06 | 1996-07-30 | Cyberonics, Inc. | Treatment of motility disorders by nerve stimulation |
EP0840590A1 (en) | 1995-07-06 | 1998-05-13 | Lee John Milligan | Septum nerve stimulator |
US5707400A (en) | 1995-09-19 | 1998-01-13 | Cyberonics, Inc. | Treating refractory hypertension by nerve stimulation |
WO1997015348A1 (en) | 1995-10-11 | 1997-05-01 | Regeneration Technology | Bio-active frequency generator and method |
US5700282A (en) | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
AR004691A1 (en) | 1995-10-27 | 1999-03-10 | Astrazeneca Ab | NEW DERIVATIVES OF [3-ALCOXI-PENOXI -) - ETIL] -DIALKYLAMINE, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, THEIR USE AS LOCAL ANESTHETICS AND A PROCEDURE FOR THEIR PREPARATION |
US6073048A (en) | 1995-11-17 | 2000-06-06 | Medtronic, Inc. | Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure |
SE9504662D0 (en) | 1995-12-22 | 1995-12-22 | Astra Pharma Inc | New compounds |
US5713922A (en) | 1996-04-25 | 1998-02-03 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain |
SE9601421D0 (en) | 1996-04-12 | 1996-04-12 | Astra Ab | New composition |
US6094598A (en) | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US6006134A (en) | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US5711316A (en) | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US6132384A (en) | 1996-06-26 | 2000-10-17 | Medtronic, Inc. | Sensor, method of sensor implant and system for treatment of respiratory disorders |
US5983141A (en) | 1996-06-27 | 1999-11-09 | Radionics, Inc. | Method and apparatus for altering neural tissue function |
US6246912B1 (en) | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US6026326A (en) | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US6093145A (en) | 1997-02-10 | 2000-07-25 | Aesculap Ag & Co. Kg | Brain spatula |
US5865843A (en) | 1997-04-23 | 1999-02-02 | Medtronic Inc. | Medical neurological lead with integral fixation mechanism |
US5861014A (en) | 1997-04-30 | 1999-01-19 | Medtronic, Inc. | Method and apparatus for sensing a stimulating gastrointestinal tract on-demand |
USRE40279E1 (en) | 1997-06-26 | 2008-04-29 | Sherwood Services Ag | Method and system for neural tissue modification |
US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US20050281751A1 (en) | 1997-07-21 | 2005-12-22 | Bruce Levin | Directed intranasal administration of pharmaceutical agents |
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US6458157B1 (en) | 1997-08-04 | 2002-10-01 | Suaning Gregg Joergen | Retinal stimulator |
US5824027A (en) | 1997-08-14 | 1998-10-20 | Simon Fraser University | Nerve cuff having one or more isolated chambers |
US6141590A (en) | 1997-09-25 | 2000-10-31 | Medtronic, Inc. | System and method for respiration-modulated pacing |
US5938688A (en) | 1997-10-22 | 1999-08-17 | Cornell Research Foundation, Inc. | Deep brain stimulation method |
US6016449A (en) | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6647296B2 (en) | 1997-10-27 | 2003-11-11 | Neuropace, Inc. | Implantable apparatus for treating neurological disorders |
US6146380A (en) | 1998-01-09 | 2000-11-14 | Radionics, Inc. | Bent tip electrical surgical probe |
US6594765B2 (en) * | 1998-09-29 | 2003-07-15 | Softvault Systems, Inc. | Method and system for embedded, automated, component-level control of computer systems and other complex systems |
US6251126B1 (en) | 1998-04-23 | 2001-06-26 | Medtronic Inc | Method and apparatus for synchronized treatment of obstructive sleep apnea |
US6058331A (en) | 1998-04-27 | 2000-05-02 | Medtronic, Inc. | Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control |
US6292695B1 (en) | 1998-06-19 | 2001-09-18 | Wilton W. Webster, Jr. | Method and apparatus for transvascular treatment of tachycardia and fibrillation |
CA2275370A1 (en) | 1998-06-24 | 1999-12-24 | Owens-Illinois Closure Inc. | Liquid containment and dispensing device |
US6366813B1 (en) | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US7599736B2 (en) | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US7277758B2 (en) | 1998-08-05 | 2007-10-02 | Neurovista Corporation | Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder |
US6104957A (en) | 1998-08-21 | 2000-08-15 | Alo; Kenneth M. | Epidural nerve root stimulation with lead placement method |
US6615081B1 (en) | 1998-10-26 | 2003-09-02 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator |
US6366814B1 (en) | 1998-10-26 | 2002-04-02 | Birinder R. Boveja | External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders |
US6356788B2 (en) | 1998-10-26 | 2002-03-12 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US6564102B1 (en) | 1998-10-26 | 2003-05-13 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator |
US20060122660A1 (en) | 1998-10-26 | 2006-06-08 | Boveja Birinder R | Method and system for modulating sacral nerves and/or its branches in a patient to provide therapy for urological disorders and/or fecal incontinence, using rectangular and/or complex electrical pulses |
US7076307B2 (en) | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
US6668191B1 (en) | 1998-10-26 | 2003-12-23 | Birinder R. Boveja | Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator |
US6269270B1 (en) | 1998-10-26 | 2001-07-31 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of Dementia and Alzheimer's disease utilizing an implantable lead and external stimulator |
US20030212440A1 (en) | 2002-05-09 | 2003-11-13 | Boveja Birinder R. | Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system |
US6205359B1 (en) | 1998-10-26 | 2001-03-20 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US6161044A (en) | 1998-11-23 | 2000-12-12 | Synaptic Corporation | Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation |
AU2862200A (en) | 1999-01-27 | 2000-08-18 | Bruce H. Levin | Compositions, kits, apparatus, and methods for inhibiting cerebral neurovasculardisorders and muscular headaches |
US8019421B2 (en) | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
US6178349B1 (en) | 1999-04-15 | 2001-01-23 | Medtronic, Inc. | Drug delivery neural stimulation device for treatment of cardiovascular disorders |
US20010025192A1 (en) | 1999-04-29 | 2001-09-27 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
JP2001013640A (en) | 1999-07-01 | 2001-01-19 | Fuji Photo Film Co Ltd | Film unit with lens |
US6353792B1 (en) | 1999-07-06 | 2002-03-05 | Sudhir Murthy | System and method for remote communication of traffic monitoring device data |
US6308105B1 (en) | 1999-07-15 | 2001-10-23 | Medtronic Inc. | Medical electrical stimulation system using an electrode assembly having opposing semi-circular arms |
US6272377B1 (en) | 1999-10-01 | 2001-08-07 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with arrhythmia prediction and prevention |
US6690971B2 (en) | 1999-11-30 | 2004-02-10 | Biotronik Mess - Und Therapiegeraete Gmbh & Co. Ingenieurbuero Berlin | Device for regulating heart rate and heart pumping force |
TW483768B (en) | 1999-12-07 | 2002-04-21 | George Mason Universityi | Adaptive electric field modulation of neural systems |
US6438423B1 (en) | 2000-01-20 | 2002-08-20 | Electrocore Technique, Llc | Method of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain |
US6356786B1 (en) | 2000-01-20 | 2002-03-12 | Electrocore Techniques, Llc | Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain |
US7865237B2 (en) | 2000-01-20 | 2011-01-04 | The Cleveland Clinic Foundation | Methods and systems of achieving hemodynamic control through neuromodulation |
US6356787B1 (en) | 2000-02-24 | 2002-03-12 | Electro Core Techniques, Llc | Method of treating facial blushing by electrical stimulation of the sympathetic nerve chain |
US6885888B2 (en) | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
US20060085046A1 (en) | 2000-01-20 | 2006-04-20 | Ali Rezai | Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system |
AU3361901A (en) | 2000-02-17 | 2001-08-27 | Neurodan A/S | Methods and implantable systems for neural sensing and nerve stimulation |
US7805188B2 (en) | 2000-03-24 | 2010-09-28 | Micor, Inc. | Anesthesia conduction catheter for delivery of electrical stimulus |
WO2001085094A2 (en) | 2000-05-08 | 2001-11-15 | Brainsgate Ltd. | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
US6853858B2 (en) | 2000-05-08 | 2005-02-08 | Brainsgate, Ltd. | Administration of anti-inflammatory drugs into the central nervous system |
US7146209B2 (en) | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
US7117033B2 (en) | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6511500B1 (en) | 2000-06-06 | 2003-01-28 | Marc Mounir Rahme | Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects |
US6526318B1 (en) * | 2000-06-16 | 2003-02-25 | Mehdi M. Ansarinia | Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions |
US6405079B1 (en) | 2000-09-22 | 2002-06-11 | Mehdi M. Ansarinia | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions |
US7158832B2 (en) | 2000-09-27 | 2007-01-02 | Cvrx, Inc. | Electrode designs and methods of use for cardiovascular reflex control devices |
US8086314B1 (en) | 2000-09-27 | 2011-12-27 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US7616997B2 (en) | 2000-09-27 | 2009-11-10 | Kieval Robert S | Devices and methods for cardiovascular reflex control via coupled electrodes |
JP2004512105A (en) | 2000-10-26 | 2004-04-22 | メドトロニック・インコーポレーテッド | Method and apparatus for protecting heart tissue from seizures |
DE60134878D1 (en) | 2000-10-26 | 2008-08-28 | Medtronic Inc | DEVICE FOR THE ELECTRICAL STIMULATION OF THE NERVOUS SYSTEM FOR THE THERAPY OF VENTRICULAR MALFUNCTIONS, HEART FAILURES AND OTHER CARDIAL STATES |
US6832114B1 (en) | 2000-11-21 | 2004-12-14 | Advanced Bionics Corporation | Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes |
US6633779B1 (en) | 2000-11-27 | 2003-10-14 | Science Medicus, Inc. | Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms |
US7493172B2 (en) | 2001-01-30 | 2009-02-17 | Boston Scientific Neuromodulation Corp. | Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition |
US6788975B1 (en) | 2001-01-30 | 2004-09-07 | Advanced Bionics Corporation | Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy |
US20060064140A1 (en) | 2001-01-30 | 2006-03-23 | Whitehurst Todd K | Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder |
US6735475B1 (en) | 2001-01-30 | 2004-05-11 | Advanced Bionics Corporation | Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain |
US6564096B2 (en) | 2001-02-28 | 2003-05-13 | Robert A. Mest | Method and system for treatment of tachycardia and fibrillation |
US7167751B1 (en) | 2001-03-01 | 2007-01-23 | Advanced Bionics Corporation | Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation |
US7047078B2 (en) | 2001-03-30 | 2006-05-16 | Case Western Reserve University | Methods for stimulating components in, on, or near the pudendal nerve or its branches to achieve selective physiologic responses |
US7369897B2 (en) | 2001-04-19 | 2008-05-06 | Neuro And Cardiac Technologies, Llc | Method and system of remotely controlling electrical pulses provided to nerve tissue(s) by an implanted stimulator system for neuromodulation therapies |
EP1395330A1 (en) | 2001-04-20 | 2004-03-10 | The Board of Regents for the University of Oklahoma | Cardiac neuromodulation and methods of using same |
JP2002330934A (en) | 2001-05-08 | 2002-11-19 | Tanita Corp | Autonomic nerve activity measuring instrument |
US20090118780A1 (en) | 2001-07-23 | 2009-05-07 | Dilorenzo Daniel John | Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions |
US6554809B2 (en) | 2001-08-02 | 2003-04-29 | Teodulo Aves | Epidural catheter needle |
US7077842B1 (en) | 2001-08-03 | 2006-07-18 | Cosman Jr Eric R | Over-the-wire high frequency electrode |
IL160654A0 (en) | 2001-08-28 | 2004-07-25 | Medtronic Inc | Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation |
US6760626B1 (en) | 2001-08-29 | 2004-07-06 | Birinder R. Boveja | Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system |
US7778711B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
US7885709B2 (en) | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
US20030065374A1 (en) | 2001-10-01 | 2003-04-03 | Medtronic, Inc. | Active fixation lead with helix extension indicator |
US20130178829A1 (en) | 2001-10-23 | 2013-07-11 | Autonomic Technologies, Inc. | Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system |
US6721603B2 (en) | 2002-01-25 | 2004-04-13 | Cyberonics, Inc. | Nerve stimulation as a treatment for pain |
US7113033B2 (en) | 2002-01-31 | 2006-09-26 | Qualcomm Incorporated | Variable impedance load for a variable gain radio frequency amplifier |
US7477945B2 (en) | 2002-02-01 | 2009-01-13 | The Cleveland Clinic Foundation | Delivery device for stimulating the sympathetic nerve chain |
US7702386B2 (en) | 2002-03-22 | 2010-04-20 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes |
US7239912B2 (en) | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
US7551964B2 (en) | 2002-03-22 | 2009-06-23 | Leptos Biomedical, Inc. | Splanchnic nerve stimulation for treatment of obesity |
US7236822B2 (en) | 2002-03-22 | 2007-06-26 | Leptos Biomedical, Inc. | Wireless electric modulation of sympathetic nervous system |
US7689276B2 (en) | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
US7123959B2 (en) | 2002-03-25 | 2006-10-17 | Cardiac Pacemakers, Inc. | Method and apparatus for preventing cardiac arrhythmias with endovascular stimulation |
DE10213919A1 (en) | 2002-03-28 | 2003-10-09 | Imre Jordy | Medical instrument and process for its manufacture |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
US7191012B2 (en) | 2003-05-11 | 2007-03-13 | Boveja Birinder R | Method and system for providing pulsed electrical stimulation to a craniel nerve of a patient to provide therapy for neurological and neuropsychiatric disorders |
US20060004423A1 (en) | 2002-05-09 | 2006-01-05 | Boveja Birinder R | Methods and systems to provide therapy or alleviate symptoms of chronic headache, transformed migraine, and occipital neuralgia by providing rectangular and/or complex electrical pulses to occipital nerves |
US20050209654A1 (en) | 2002-05-09 | 2005-09-22 | Boveja Birinder R | Method and system for providing adjunct (add-on) therapy for depression, anxiety and obsessive-compulsive disorders by providing electrical pulses to vagus nerve(s) |
US20070067004A1 (en) | 2002-05-09 | 2007-03-22 | Boveja Birinder R | Methods and systems for modulating the vagus nerve (10th cranial nerve) to provide therapy for neurological, and neuropsychiatric disorders |
US20050216070A1 (en) | 2002-05-09 | 2005-09-29 | Boveja Birinder R | Method and system for providing therapy for migraine/chronic headache by providing electrical pulses to vagus nerve(s) |
US20050154426A1 (en) | 2002-05-09 | 2005-07-14 | Boveja Birinder R. | Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation |
US8036745B2 (en) | 2004-06-10 | 2011-10-11 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic pacing therapy during and following a medical procedure, clinical trauma or pathology |
US7003352B1 (en) | 2002-05-24 | 2006-02-21 | Advanced Bionics Corporation | Treatment of epilepsy by brain stimulation |
US7860570B2 (en) | 2002-06-20 | 2010-12-28 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US7292890B2 (en) | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US7203548B2 (en) | 2002-06-20 | 2007-04-10 | Advanced Bionics Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US7285118B1 (en) | 2002-07-18 | 2007-10-23 | Functional Neuroscience Inc. | Brain stimulation lead used for lesioning |
US7027860B2 (en) | 2002-08-29 | 2006-04-11 | Department Of Veterans Affairs | Microstimulator neural prosthesis |
JP2006515999A (en) | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | Surgical tools and techniques for stimulation |
US7561919B2 (en) | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
US7294101B2 (en) | 2002-12-21 | 2007-11-13 | Neuropace, Inc. | Means and methods for treating headaches |
EP1587576A2 (en) | 2003-01-03 | 2005-10-26 | Advanced Neuromodulation Systems Inc. | SYSTEM AND METHOD FOR STIMULATION OF A PERSON’S BRAIN STEM |
US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
US7844338B2 (en) | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
IL154801A0 (en) | 2003-03-06 | 2003-10-31 | Karotix Internat Ltd | Multi-channel and multi-dimensional system and method |
US20060074450A1 (en) | 2003-05-11 | 2006-04-06 | Boveja Birinder R | System for providing electrical pulses to nerve and/or muscle using an implanted stimulator |
US7620454B2 (en) | 2003-05-19 | 2009-11-17 | Medtronic, Inc. | Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
US7340298B1 (en) | 2003-09-03 | 2008-03-04 | Coaxia, Inc. | Enhancement of cerebral blood flow by electrical nerve stimulation |
US20050102006A1 (en) | 2003-09-25 | 2005-05-12 | Whitehurst Todd K. | Skull-mounted electrical stimulation system |
US20050075702A1 (en) | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US7418292B2 (en) | 2003-10-01 | 2008-08-26 | Medtronic, Inc. | Device and method for attenuating an immune response |
US20050143378A1 (en) | 2003-12-29 | 2005-06-30 | Yun Anthony J. | Treatment of conditions through pharmacological modulation of the autonomic nervous system |
US20050153885A1 (en) * | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
US20090312817A1 (en) | 2003-11-26 | 2009-12-17 | Wicab, Inc. | Systems and methods for altering brain and body functions and for treating conditions and diseases of the same |
US7769461B2 (en) | 2003-12-19 | 2010-08-03 | Boston Scientific Neuromodulation Corporation | Skull-mounted electrical stimulation system and method for treating patients |
US8024050B2 (en) | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
US7901351B2 (en) | 2003-12-24 | 2011-03-08 | Medical Innovations, Llc | Fiberoptic otoscope system |
JP4879754B2 (en) | 2004-01-22 | 2012-02-22 | リハブトロニクス インコーポレーテッド | Method for carrying electrical current to body tissue via implanted non-active conductor |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
GB0409806D0 (en) | 2004-04-30 | 2004-06-09 | Univ Brunel | Nerve blocking method and system |
WO2006007048A2 (en) | 2004-05-04 | 2006-01-19 | The Cleveland Clinic Foundation | Methods of treating medical conditions by neuromodulation of the sympathetic nervous system |
US7286879B2 (en) | 2004-07-16 | 2007-10-23 | Boston Scientific Scimed, Inc. | Method of stimulating fastigium nucleus to treat neurological disorders |
US7623924B2 (en) | 2004-08-31 | 2009-11-24 | Leptos Biomedical, Inc. | Devices and methods for gynecologic hormone modulation in mammals |
WO2006034305A2 (en) | 2004-09-21 | 2006-03-30 | University Of Florida Research Foundation, Inc. | Multiple lead method for deep brain stimulation |
US8083671B2 (en) | 2004-09-30 | 2011-12-27 | Boston Scientific Scimed, Inc. | Fluid delivery system for use with an endoscope |
US7167755B2 (en) * | 2004-10-05 | 2007-01-23 | Cardiac Pacemakers, Inc. | Adaptive software configuration for a medical device |
US8175705B2 (en) | 2004-10-12 | 2012-05-08 | Cardiac Pacemakers, Inc. | System and method for sustained baroreflex stimulation |
WO2006044694A2 (en) | 2004-10-15 | 2006-04-27 | Palo Alto Investors | Methods and compositions for treating a disease condition in a subject |
US7734340B2 (en) | 2004-10-21 | 2010-06-08 | Advanced Neuromodulation Systems, Inc. | Stimulation design for neuromodulation |
US20070250119A1 (en) * | 2005-01-11 | 2007-10-25 | Wicab, Inc. | Systems and methods for altering brain and body functions and for treating conditions and diseases of the same |
US8788044B2 (en) | 2005-01-21 | 2014-07-22 | Michael Sasha John | Systems and methods for tissue stimulation in medical treatment |
DE102005003735B4 (en) | 2005-01-26 | 2008-04-03 | Cerbomed Gmbh | Device for transcutaneous stimulation of a nerve of the human body |
US8600521B2 (en) | 2005-01-27 | 2013-12-03 | Cyberonics, Inc. | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity |
US7561918B2 (en) | 2005-01-28 | 2009-07-14 | Cyberonics, Inc. | Autocapture in a neurostimulator |
US20060206165A1 (en) | 2005-03-14 | 2006-09-14 | Jaax Kristen N | Occipital nerve stimulation to treat headaches and other conditions |
US7702385B2 (en) | 2005-11-16 | 2010-04-20 | Boston Scientific Neuromodulation Corporation | Electrode contact configurations for an implantable stimulator |
US7853321B2 (en) | 2005-03-14 | 2010-12-14 | Boston Scientific Neuromodulation Corporation | Stimulation of a stimulation site within the neck or head |
US7640057B2 (en) | 2005-04-25 | 2009-12-29 | Cardiac Pacemakers, Inc. | Methods of providing neural markers for sensed autonomic nervous system activity |
US8244360B2 (en) | 2005-06-09 | 2012-08-14 | Medtronic, Inc. | Regional therapies for treatment of pain |
US7706874B2 (en) | 2005-07-28 | 2010-04-27 | Cyberonics, Inc. | Stimulating cranial nerve to treat disorders associated with the thyroid gland |
US20070027484A1 (en) | 2005-07-28 | 2007-02-01 | Cyberonics, Inc. | Autonomic nerve stimulation to treat a pancreatic disorder |
US20070027486A1 (en) | 2005-07-29 | 2007-02-01 | Cyberonics, Inc. | Medical devices for enhancing intrinsic neural activity |
US7499752B2 (en) | 2005-07-29 | 2009-03-03 | Cyberonics, Inc. | Selective nerve stimulation for the treatment of eating disorders |
US7684858B2 (en) | 2005-09-21 | 2010-03-23 | Boston Scientific Neuromodulation Corporation | Methods and systems for placing an implanted stimulator for stimulating tissue |
US20070100411A1 (en) | 2005-10-27 | 2007-05-03 | Medtronic, Inc. | Implantable medical electrical stimulation lead fixation method and apparatus |
US20070106143A1 (en) | 2005-11-08 | 2007-05-10 | Flaherty J C | Electrode arrays and related methods |
EP1948301B8 (en) | 2005-11-10 | 2014-03-12 | ElectroCore LLC | Electrical stimulation treatment of bronchial constriction |
US9037247B2 (en) | 2005-11-10 | 2015-05-19 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
US7763034B2 (en) | 2006-01-24 | 2010-07-27 | Medtronic, Inc. | Transobturator lead implantation for pelvic floor stimulation |
EP1984064A4 (en) | 2006-02-10 | 2009-11-11 | Electrocore Inc | Methods and apparatus for treating anaphylaxis using electrical modulation |
ES2573323T3 (en) | 2006-03-29 | 2016-06-07 | Dignity Health | Electrical stimulation of cranial nerve microburst for the treatment of medical conditions |
US20080183237A1 (en) | 2006-04-18 | 2008-07-31 | Electrocore, Inc. | Methods And Apparatus For Treating Ileus Condition Using Electrical Signals |
US20070255368A1 (en) | 2006-04-28 | 2007-11-01 | Bonde Eric H | Implantable medical electrical stimulation lead with distal fixation and method |
US8892214B2 (en) | 2006-04-28 | 2014-11-18 | Medtronic, Inc. | Multi-electrode peripheral nerve evaluation lead and related system and method of use |
US20080027346A1 (en) | 2006-05-22 | 2008-01-31 | The Trustees Of The University Of Pennsylvania | Method and device for the recording, localization and stimulation-based mapping of epileptic seizures and brain function utilizing the intracranial and extracranial cerebral vasculature and/or central and/or peripheral nervous system |
CA2656023A1 (en) | 2006-06-19 | 2007-12-27 | Highland Instruments, Inc. | Apparatus and method for stimulation of biological tissue |
US7894907B2 (en) | 2006-06-20 | 2011-02-22 | Ebr Systems, Inc. | Systems and methods for implantable leadless nerve stimulation |
US7660632B2 (en) | 2006-06-30 | 2010-02-09 | Ric Investments, Llc | Method and apparatus for hypoglossal nerve stimulation |
US8209013B2 (en) | 2006-09-14 | 2012-06-26 | Cardiac Pacemakers, Inc. | Therapeutic electrical stimulation that avoids undesirable activation |
US8688238B2 (en) | 2006-10-31 | 2014-04-01 | Medtronic, Inc. | Implantable medical elongated member including fixation elements along an interior surface |
US9492657B2 (en) | 2006-11-30 | 2016-11-15 | Medtronic, Inc. | Method of implanting a medical device including a fixation element |
US7765012B2 (en) | 2006-11-30 | 2010-07-27 | Medtronic, Inc. | Implantable medical device including a conductive fixation element |
US10856904B2 (en) | 2006-11-30 | 2020-12-08 | Medtronic, Inc. | Flexible introducer |
US7744618B2 (en) | 2006-12-07 | 2010-06-29 | Cardiac Pacemakers, Inc. | Device and method for modulating renal function |
US20080183246A1 (en) | 2007-01-26 | 2008-07-31 | Cyberonics, Inc. | Method, apparatus and system for guiding a procedure relating to an implantable medical device |
US7917230B2 (en) | 2007-01-30 | 2011-03-29 | Cardiac Pacemakers, Inc. | Neurostimulating lead having a stent-like anchor |
US20080262566A1 (en) | 2007-04-23 | 2008-10-23 | Boston Scientific Neuromodulation Corporation | Methods and systems of treating medication overuse headache |
US8954162B2 (en) | 2007-04-25 | 2015-02-10 | Medtronic, Inc. | Medical device implantation |
AU2008260076A1 (en) | 2007-05-30 | 2008-12-11 | The Cleveland Clinic Foundation | Apparatus and method for treating headache and/or facial pain |
US8027737B2 (en) | 2007-08-01 | 2011-09-27 | Intelect Medical, Inc. | Lead extension with input capabilities |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
US7848816B1 (en) | 2007-12-27 | 2010-12-07 | Pacesetter, Inc. | Acquiring nerve activity from carotid body and/or sinus |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
WO2009129480A2 (en) | 2008-04-18 | 2009-10-22 | Medtronic, Inc. | Psychiatric disorder therapy control |
EP2192947A1 (en) | 2008-04-30 | 2010-06-09 | Medtronic, Inc. | Techniques for placing medical leads for electrical stimulation of nerve tissue |
US8473062B2 (en) | 2008-05-01 | 2013-06-25 | Autonomic Technologies, Inc. | Method and device for the treatment of headache |
US8151795B2 (en) * | 2008-06-30 | 2012-04-10 | Linde Ag | Method of demand valve oxygen therapy for rapid abort of cluster headache |
US8195297B2 (en) | 2008-10-13 | 2012-06-05 | E-Pacing, Inc. | Devices and methods for electrical stimulation of the diaphragm and nerves |
US8412336B2 (en) | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
US20130110195A1 (en) | 2009-01-15 | 2013-05-02 | Autonomic Technologies, Inc. | Neurostimulator system, apparatus, and method |
US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
US20130116745A1 (en) | 2009-01-15 | 2013-05-09 | Autonomic Technologies, Inc. | Neurostimulator system, apparatus, and method |
ES2540127T3 (en) | 2009-01-16 | 2015-07-08 | The Cleveland Clinic Foundation | Surgical guide for a pterygopalatine fossa therapy device |
US8321030B2 (en) | 2009-04-20 | 2012-11-27 | Advanced Neuromodulation Systems, Inc. | Esophageal activity modulated obesity therapy |
-
2010
- 2010-01-15 US US12/688,524 patent/US9320908B2/en active Active
-
2015
- 2015-09-09 US US14/849,351 patent/US20150374998A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8055347B2 (en) * | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US20080021341A1 (en) * | 2006-06-23 | 2008-01-24 | Neurovista Corporation A Delware Corporation | Methods and Systems for Facilitating Clinical Trials |
US20080221921A1 (en) * | 2007-01-19 | 2008-09-11 | Ventrassist Pty Ltd | Method of conducting a clinical trial |
US20100211123A1 (en) * | 2009-02-19 | 2010-08-19 | Stubbs Scott R | Systems and methods for providing arrhythmia therapy in mri environments |
US8165691B2 (en) * | 2009-10-19 | 2012-04-24 | Medtronic, Inc. | Implantable medical device with selectively configurable exposure operating mode programming options |
US20110125214A1 (en) * | 2009-11-25 | 2011-05-26 | Medtronic, Inc. | Medical electrical stimulation with external simulated case electrode |
US20110125215A1 (en) * | 2009-11-25 | 2011-05-26 | Medtronic, Inc. | Medical electrical stimulation with implantable simulated case electrode |
US20120302912A1 (en) * | 2011-05-27 | 2012-11-29 | Boston Scientific Neuromodulation Corporation | Collection of clinical data for graphical representation and analysis |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10716940B2 (en) | 2009-10-20 | 2020-07-21 | Nyxoah SA | Implant unit for modulation of small diameter nerves |
US11857791B2 (en) | 2009-10-20 | 2024-01-02 | Nyxoah SA | Arced implant unit for modulation of nerves |
US10751537B2 (en) | 2009-10-20 | 2020-08-25 | Nyxoah SA | Arced implant unit for modulation of nerves |
US9943686B2 (en) | 2009-10-20 | 2018-04-17 | Nyxoah SA | Method and device for treating sleep apnea based on tongue movement |
US9950166B2 (en) | 2009-10-20 | 2018-04-24 | Nyxoah SA | Acred implant unit for modulation of nerves |
US9849289B2 (en) | 2009-10-20 | 2017-12-26 | Nyxoah SA | Device and method for snoring detection and control |
US11273307B2 (en) | 2009-10-20 | 2022-03-15 | Nyxoah SA | Method and device for treating sleep apnea |
US10898717B2 (en) | 2009-10-20 | 2021-01-26 | Nyxoah SA | Device and method for snoring detection and control |
US10052097B2 (en) | 2012-07-26 | 2018-08-21 | Nyxoah SA | Implant unit delivery tool |
US9855032B2 (en) | 2012-07-26 | 2018-01-02 | Nyxoah SA | Transcutaneous power conveyance device |
US10716560B2 (en) | 2012-07-26 | 2020-07-21 | Nyxoah SA | Implant unit delivery tool |
US10814137B2 (en) | 2012-07-26 | 2020-10-27 | Nyxoah SA | Transcutaneous power conveyance device |
US10918376B2 (en) | 2012-07-26 | 2021-02-16 | Nyxoah SA | Therapy protocol activation triggered based on initial coupling |
US11253712B2 (en) | 2012-07-26 | 2022-02-22 | Nyxoah SA | Sleep disordered breathing treatment apparatus |
US11730469B2 (en) | 2012-07-26 | 2023-08-22 | Nyxoah SA | Implant unit delivery tool |
US10512782B2 (en) | 2013-06-17 | 2019-12-24 | Nyxoah SA | Remote monitoring and updating of a medical device control unit |
US11298549B2 (en) | 2013-06-17 | 2022-04-12 | Nyxoah SA | Control housing for disposable patch |
US11642534B2 (en) | 2013-06-17 | 2023-05-09 | Nyxoah SA | Programmable external control unit |
US9643022B2 (en) | 2013-06-17 | 2017-05-09 | Nyxoah SA | Flexible control housing for disposable patch |
Also Published As
Publication number | Publication date |
---|---|
US9320908B2 (en) | 2016-04-26 |
US20100179617A1 (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9320908B2 (en) | Approval per use implanted neurostimulator | |
US20230166130A1 (en) | Medical device | |
US10279186B2 (en) | Automated verification of MRI compatibility of active implantable medical device | |
EP1583585B1 (en) | Seamless communication between an implantable medical device and a remote system | |
US7831828B2 (en) | System and method for securely authenticating a data exchange session with an implantable medical device | |
US8666488B2 (en) | Post-download patient data protection in a medical device | |
US7729929B2 (en) | Method and apparatus for delivery of medical items on an electronic prescription | |
CN112368779A (en) | Medical device and safety control system | |
US20020052539A1 (en) | System and method for emergency communication between an implantable medical device and a remote computer system or health care provider | |
US20020082665A1 (en) | System and method of communicating between an implantable medical device and a remote computer system or health care provider | |
CN102172419A (en) | Security features for a medical infusion pump | |
WO2002056762A9 (en) | System and method of automated invoicing for communications between an implantable medical device and a remote computer system for health provider | |
US20150227909A1 (en) | Medical Device Payment System | |
US20140249658A1 (en) | Condition status-based medical device system and operation | |
US20140180870A1 (en) | Methods, systems, and devices for authorizing performance of a medical task by an implantable medical device | |
Levy | Device complication and failure management in neuromodulation | |
WO2022245878A1 (en) | Neurostimulation parameter authentication and expiration system for neurostimulation | |
CA2822954A1 (en) | Method for treatment billing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT, TEXAS Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:AUTONOMIC TECHNOLOGIES, INC.;REEL/FRAME:037405/0600 Effective date: 20151229 |
|
AS | Assignment |
Owner name: AUTONOMIC TECHNOLOGIES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FLETCHER, KELLIE S.;PLESS, BENJAMIN DAVID;CAPARSO, ANTHONY;AND OTHERS;REEL/FRAME:037577/0162 Effective date: 20100125 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |